JUNIPER-NETWORKS
23.2.2022 09:02:08 CET | Business Wire | Press release
Juniper Networks, (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Sparkle , the first international service provider in Italy and among the top global operators, has deployed Juniper’s 400G solutions to meet increasing bandwidth demands reliably and cost-effectively. In addition, Juniper’s experience-first network solution supports Sparkle’s sustainability goals through power and space savings in its points of presence.
With its global Tier-1 IP Transit backbone “Seabone”, Sparkle is a Top 5 global IP player, providing high-speed and reliable Internet connectivity to ISPs and content providers worldwide. The service is delivered over an advanced proprietary network of over 600,000 km of fiber including major regional systems in Europe, the Mediterranean and the Americas, plus ownership of major international submarine cables. As Sparkle continues to innovate in the cloud era, Juniper Networks’ 400G solution helps Sparkle fulfill its mission to provide “bandwidth hungry” customers with customized solutions that deliver a superior end-user experience, competitive cost and top performance in the international telecommunications market.
News Highlights:
- Juniper’s technology enables Sparkle to reduce space and power consumption in its core PoPs. 400G connections are also easier to manage with fewer overall ports. Juniper’s innovative silicon advancements reduce watts consumed per gigabit, allowing for high speed data transmissions at lower power levels.
- Sparkle has deployed Juniper’s PTX Series Routers , high-performance, cloud-optimized platforms that enable smooth migration to 400G while delivering the bandwidth, flexibility and maturity that comes with Juniper’s latest generation silicon.
- The PTX Series offers ultra-high port density, 400GbE support, flexible filtering and a reliable network operating system that has been powering generations of high-performance solutions.
- 400G technology provides Sparkle with a new level of scale. 400G optical transceiver modules deliver a lower cost-per-bit by delivering the same bandwidth in less physical space. A 400G-capable network is a key step for Tier-1 providers like Sparkle, who are grappling with relentless traffic growth.
Supporting quotes:
“The 400G platform from Juniper will be a key tool in our ongoing challenge to match constantly growing traffic demands at very competitive price-per-port in the context of premium space and power costs, without sacrificing reliability and features. In addition, the better economy of scale and a denser configuration supports the high standard for eco-sustainable design and energy efficiency to which we work.”
- Enrico Bagnasco, Chief Technology Officer, Sparkle
“Juniper is pleased to support customers like Sparkle as they balance their sustainability journey with achieving their commercial goals and customer experience requirements. We share Sparkle’s vision of having a significantly positive impact on the environment and believe that innovation in sustainable technology is as important as reducing our environmental footprint.”
- Raj Yavatkar, Chief Technology Officer, Juniper Networks
Additional resources:
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net ) or connect with Juniper on Twitter , LinkedIn and Facebook .
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
category-serviceprovider
View source version on businesswire.com: https://www.businesswire.com/news/home/20220223005157/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
